Martin Rosendale, Chief Executive Officer
Mr. Rosendale joined Cytomedix, Inc. in March 2008 as COO and he was appointed Chief Executive Officer in July 2008. Prior to joining Cytomedix, Mr. Rosendale was Chief Executive Officer of Core Dynamics, Inc. where he managed their Israel based R&D program and initiated U.S. commercial operations for cryobiology and cell lyophilization technologies. Mr. Rosendale has more than 24 years of specialty medical experience. He has held leadership positions for the past 15 years with American Red Cross, SangStat, North American Vaccine and ZLB Bioplasma, in addition to serving on the boards of the Transplant Recipients International Organization and the American Red Cross Biomedical Services, San Jose Region. Mr. Rosendale earned a Bachelor of Science degree in Microbiology from California State University.
Andrew Maslan, CPA, Chief Financial Officer
Mr. Maslan joined Cytomedix, Inc. in July 2005 and he was appointed Chief Financial Officer in August 2005. Prior to joining Cytomedix, Mr. Maslan served as controller for BioReliance Corporation, he was a principal with GlobeTraders, Inc., and a senior accountant for Providence Laboratory Associates. He began his professional career serving as an auditor with KPMG Peat Marwick, earned a Bachelor of Science degree in Accountancy from Miami University in Oxford, Ohio, and he is a Certified Public Accountant in the State of Maryland.
 
Carelyn Fylling, R.N., M.S.N., Vice President, Professional Services
Ms. Fylling joined the new management team at Cytomedix, Inc. in December 2001 having joined the Company’s predecessor Curative Health Services in 1988. At Curative, Ms. Fylling helped design a national wound database, developed clinical protocols, conducted outcome studies and trained physicians and nurses in comprehensive wound management. Prior to joining Curative, Ms. Fylling was Director of Training and Program Development at the International Diabetes Center in Minneapolis, Minnesota and served on the National Board of Directors of the American Diabetes Association. In 1980, Ms. Fylling received the prestigious Ames Award for Outstanding Educator in the Field of Diabetes.
David A. Hotchkiss, Vice President, Sales and Marketing
Mr. Hotchkiss joined Cytomedix, Inc. in October 2006. Prior to joining Cytomedix, Mr Hotchkiss served as VP Sales and Marketing for Coloplast Corp., where he built successful teams.  Mr. Hotchkiss has spent over 15 years in the wound care market and has substantial sales, leadership and marketing experience in senior sales and marketing roles with Carrington Laboratories, Oclassen Pharmaceuticals, and Rhone Poulenc Rorer. He earned a Bachelor of Business Administration degree in Marketing from the University of North Texas, and has completed advanced management studies at UCLA and JL Kellogg.
 
Peter A. Clausen, Ph.D., Vice President, Business Development
Dr. Clausen joined Cytomedix, Inc. in September 2008 after consulting to the Company since May 2008. Prior to joining Cytomedix, Dr. Clausen was a founding member and Vice President, Research and Development at Marligen Bioscience, a biotechnology company that develops, manufactures and markets innovative products for the life sciences market. Dr. Clausen is a seasoned biochemist with nearly 15 years experience in the biotechnology sector. Dr. Clausen completed his post-doctoral training in the Laboratory of Molecular Oncology at the National Cancer Institute where his research efforts focused in the areas of oncology, hematopoiesis, and gene therapy. Dr. Clausen earned a Bachelor of Science degree in Biochemistry from Beloit College and a Ph.D. in Biochemistry from Rush University.
David Jorden, Executive Board Director & Investor Relations
Mr. Jorden joined Cytomedix, Inc. in September 2008. He brings to Cytomedix more than 20 years of public and private company investment experience. Prior to joining Cytomedix, Mr. Jorden was responsible for equity portfolio management at Morgan Stanley's Private Wealth Management group and previously served as CFO at Genometrix, Inc., a private genomics/life sciences company. Mr. Jorden serves on the Board of Opexa Therapeutics, Inc., PLx Pharma, Inc., and DLush, a San Diego based deluxe beverage company. Mr. Jorden earned a Master of Management from the Kellogg School of Management at Northwestern University and a BBA from the University of Texas at Austin. He holds both CFA and CPA designations.
© 2009 Cytomedix.  All Rights Reserved. Site Map | Terms & Conditions